Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction
Conflict of interest JT has given Scientific advice to AlfaWassermann, Allergan, Christian Hansen, Danone, Grnenthal, Ironwood, Janssen, Kiowa Kirin, Menarini, Mylan, Neutec, Novartis, Noventure, Nutricia, Shionogi, Shire, Takeda, Theravance, Tramedico, Truvion, Tsumura, Zealand, and Zeria pharmaceuticals and has served on the Speaker bureau for Abbott, Allergan, AstraZeneca, Janssen, Kyowa Kirin, Menarini, Mylan, Novartis, Shire, Takeda, Truvion, and Zeria
Plus, there is plenty of anecdotal evidence that the pill can fail while women are on GLP-1s, leading to so-called Ozempic babies
Photonics & Lasers in Medicine , 1 (4).
Rheumatology 2010
3 Johns Hopkins Drug Discovery, Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD, 21205, USA Correspondence: Soo Kyung Bae, College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, 14662, Republic of Korea, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are peptide-derived analogs that were initially investigated to treat type 2 diabetes